MedTrace Logo

Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

NCT00815594 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-12-30

No results posted yet for this study

Summary

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Conditions

  • Bleb Vascularity
  • Conjunctival Scarring

Interventions

DRUG

bevacizumab

0.05ml, 1.25mg

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Principal Investigators

  • Liu Xuan, M.D. · An ophthalmologist in Tongren hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-03-31
Completion
2009-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00815594 on ClinicalTrials.gov